The efforts of the researchers ultimately lead to the emerging of most potent third generation ALK inhibitor drugs, which gave a special interest and clinical benefits in treatment of ALK-positive patients NSCLC who are not responding to the earlier generations of ALK inhibitors. This evidence concerns the gene ALK and non-small cell lung carcinoma.